Dry eyes and dry mouth are often the entry point to Sjögren’s syndrome, but they are not the whole disease. The clinical problem is deciding when sicca symptoms represent a local gland disorder and when they signal a systemic autoimmune condition that can affect joints, lungs, kidneys, nerves, blood counts, and lymphoma risk. That distinction matters for patients trying to understand fatigue, pain, or organ symptoms, and for clinicians deciding which tests, monitoring, and treatments are justified.

Why Sjögren’s is systemic

Sjögren’s is characterized by lymphocytic inflammation of exocrine glands, especially the lacrimal and salivary glands. B cells are unusually active, autoantibodies are common, and some patients show low complement levels, cryoglobulins, or monoclonal gammopathy. Those findings are not trivia; they identify immune activation that may correlate with extraglandular disease and, in a small subset, non-Hodgkin lymphoma.

The 2016 ACR/EULAR classification criteria reflect this biology. They assign the greatest weight to anti-SSA/Ro antibodies and focal lymphocytic sialadenitis on minor salivary gland biopsy, while objective eye and saliva tests add supporting points. Classification criteria are designed for research cohorts, not to replace clinical judgment, but they remind us that symptoms alone are insufficient.

Symptoms that deserve a wider lens

The most common daily problems remain ocular and oral dryness: gritty eyes, burning, light sensitivity, dental caries, oral candidiasis, difficulty swallowing dry foods, and sleep disruption from thirst. Treatment begins with local measures because surface inflammation and reduced secretions cause real morbidity.

Yet a careful review of systems should ask about inflammatory joint pain, parotid swelling, purpura, chronic cough, dyspnea, neuropathic burning or numbness, Raynaud phenomenon, recurrent kidney stones, muscle weakness, and constitutional symptoms. None of these proves Sjögren’s activity, but they change the evaluation.

An illustrative scenario

Consider a 48-year-old woman referred for positive antinuclear antibody testing and dry mouth. She also reports morning stiffness in the small joints, recurrent parotid swelling, and a new purpuric rash on the lower legs. In that setting, the question is not simply whether she needs artificial tears. The clinician should consider anti-SSA/Ro and anti-SSB/La antibodies, rheumatoid factor, immunoglobulin levels, complements C3 and C4, urinalysis with protein quantification, blood counts, kidney function, and, when indicated, biopsy of skin or salivary gland. The results determine whether the problem is gland-limited Sjögren’s, overlapping inflammatory arthritis, vasculitic disease, renal tubular involvement, or another diagnosis.

Treatment is matched to the tissue involved

The 2019 EULAR recommendations emphasize a tiered approach: treat dryness locally, manage pain and fatigue with individualized nonpharmacologic and symptomatic strategies, and reserve systemic immunomodulatory therapy for active organ involvement. This is not therapeutic minimalism. It is risk matching.

For ocular disease, artificial tears, lubricating ointments, punctal plugs, and prescription anti-inflammatory drops such as cyclosporine or lifitegrast may be considered by eye specialists. For xerostomia, frequent water, sugar-free lozenges, fluoride, dental prevention, saliva substitutes, and muscarinic agonists such as pilocarpine or cevimeline can help selected patients, provided contraindications are reviewed.

Hydroxychloroquine is commonly used when inflammatory arthralgia, rash, or overlapping connective tissue disease features are present, although randomized trials have not shown broad benefit for dryness. Glucocorticoids may be appropriate for short courses in specific inflammatory complications, but chronic reliance is poor strategy. Conventional or biologic disease-modifying antirheumatic drugs are chosen when the target is clear: arthritis, interstitial lung disease, renal disease, neuropathy, or vasculitis.

Rituximab, a B-cell depleting therapy, is a useful example of evidence discipline. Trials such as TEARS and TRACTISS did not demonstrate consistent improvement in primary dryness or fatigue, so it should not be viewed as a general Sjögren’s drug. In practice, it may be considered for selected severe systemic manifestations where B-cell biology is central, such as cryoglobulinemic vasculitis or lymphoma-associated scenarios, often in collaboration with other specialists.

Common misconceptions that change care

Three points repeatedly create confusion in clinic:

• Anti-SSA/Ro negativity does not automatically exclude Sjögren’s, particularly when objective dryness and biopsy findings are compelling.
• Positive antibodies do not prove that every symptom is autoimmune; medication effects, diabetes, infections, aging, and other conditions still matter.
• Dryness severity does not reliably predict systemic risk; low C4, persistent gland swelling, palpable purpura, lymphadenopathy, cryoglobulins, and monoclonal proteins are more concerning.

This is why rheumatology evaluation is less about ordering a single “Sjögren’s panel” and more about pattern recognition. A panel can support the diagnosis; it cannot stage the disease, identify organ threat, or explain competing causes of symptoms.

Monitoring beyond the symptom checklist

Follow-up should be proportional to phenotype. A patient with stable sicca symptoms and normal laboratory results may need periodic review of dental, ophthalmologic, and medication issues. A patient with systemic features needs closer surveillance. Useful monitoring parameters often include:

• Complete blood count for cytopenias.
• Creatinine and urinalysis for renal involvement, including tubular or glomerular disease.
• Complement levels, immunoglobulins, and serum protein studies when systemic activity or lymphoma risk is a concern.
• Pulmonary testing or imaging when cough, dyspnea, or abnormal examination suggests lung disease.
• Neurologic assessment when sensory loss, weakness, or autonomic symptoms are present.

Screening is not meant to alarm patients. It is meant to catch the uncommon but consequential complications early enough that treatment decisions can be deliberate rather than reactive.

Where the evidence stands

The evidence supports a disciplined view of Sjögren’s syndrome: confirm the diagnosis with objective data, treat dryness aggressively because it affects quality of life, and escalate systemic therapy only when there is a defined inflammatory target. Uncertainty remains. We still lack reliably effective disease-modifying therapy for glandular dysfunction, and current biomarkers imperfectly predict who will develop organ disease or lymphoma. Trials of targeted B-cell, interferon, and costimulation pathways may refine treatment, but today the best care is phenotype driven. Sjögren’s is not merely dry eyes and dry mouth; it is an autoimmune disease whose seriousness depends on the tissues it chooses to involve. That clinical humility protects patients from both extremes.